Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rogelio Cruz

Physician Assistant McAllen, TX Physician Assistant

NPI 1205827763 CMS profile 10625617

500 E Ridge Rd Ste 300, McAllen, TX 78503

Open in the dashboard

General payments

$13,825

295 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rogelio Cruz of McAllen, TX is reported in the CMS Open Payments database as having received $13,825 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,797 57
2024 General $2,081 52
2023 General $2,204 59
2022 General $2,439 53
2021 General $2,304 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rogelio Cruz
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Rogelio Cruz were reported at $4,797. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Rogelio Cruz Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,304 $132 $37–$438 $132
2022 $2,439 $155 $48–$522 $149
2023 $2,204 $167 $52–$557 $160
2024 $2,081 $178 $55–$600 $164
2025 $4,797 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. CVRx, Inc. $2,351 12 payments
  2. Biotronik Inc. $1,886 33 payments
  3. E.R. Squibb & Sons, L.L.C. $1,634 59 payments
  4. Abbott Laboratories $1,615 19 payments
  5. Medtronic, Inc. $900 15 payments
  6. AstraZeneca Pharmaceuticals LP $680 13 payments
  7. Amgen Inc. $678 40 payments
  8. Merck Sharp & Dohme Corporation $635 19 payments
  9. Esperion Therapeutics, Inc. $584 8 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $489 5 payments
  11. Other $2,372 72 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,478 292 payments
  2. Travel and Lodging $1,347 3 payments
Products named General payments · program years 2021–2025
  1. Barostim Neo System $2,351 12 payments
  2. CAMZYOS $904 22 payments
  3. VERQUVO $799 25 payments
  4. BioMonitor $652 11 payments
  5. NEXLETOL $584 8 payments
  6. NEXLIZET $566 5 payments
  7. Solia $542 10 payments
  8. Rivacor $538 10 payments
  9. Edora $538 10 payments
  10. Acticor $538 10 payments
  11. Other $9,457 236 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,800

Median for Physician Assistant: 241

Drug cost

$317,203

Median for Physician Assistant: $4,110

Branded share of claims

33.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 150 $137,393
Entresto Sacubitril/Valsartan Brand 56 $54,384
Xarelto Rivaroxaban Brand 33 $41,080
Farxiga Dapagliflozin Propanediol Brand 19 $22,482
Brilinta Ticagrelor Brand 24 $19,734
Jardiance Empagliflozin Brand 14 $8,899
Repatha Syringe Evolocumab Brand 11 $6,215
Ranolazine Er Ranolazine Brand 50 $4,420
Telmisartan-Hydrochlorothiazid Telmisartan/Hydrochlorothiazid Brand 22 $2,375
Metoprolol Succinate Generic 126 $2,030

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$9,493

Medicare's payments for the services billed

Medicare patients

89

Average age 78

Services billed

172

55 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%
Ischemic heart disease 61%
Arthritis 56%
Chronic kidney disease 45%
Heart failure 44%
Atrial fibrillation 38%
COPD 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $164
$164 — —
Repatha
  • Amgen Inc. $163
$163 11 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $149
$149 19 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $145
$145 — —
JARDIANCE
  • Lilly USA, LLC $119
  • Boehringer Ingelheim Pharmaceuticals, Inc. $14
$134 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record